JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Sarg Ararn
Country: Lithuania
Language: English (Spanish)
Genre: Marketing
Published (Last): 17 November 2011
Pages: 378
PDF File Size: 10.80 Mb
ePub File Size: 4.19 Mb
ISBN: 211-9-51489-755-5
Downloads: 66490
Price: Free* [*Free Regsitration Required]
Uploader: Arazahn

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Its benefits against cost in patients with lower cardiovascular risk remain an issue of debate. Abstract Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties.

Rosuvastatin in women Previous primary prevention trials have poorly demonstrated reduction in coronary events in women. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. Patients with hereditary hyperlipidaemia, particularly FH and FCH should be considered for early treatment with rosuvastatin.

Use of Rosuvastatin versus Atorvastatin in type 2 diabetes mellitus. Rosuvastatin in the elderly Randomised control trial RCT data are limited regarding statin efficacy in the elderly. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: Rosuvastatin belongs to a new generation of methane- sulphonamide pyrimidine and N -methane sulfonyl pyrrole-substituted 3, 5- dihydroxy-heptenoates. When hsCRP is included in enrolment of primary prevention, rosuvastatin produced greater benefit when compared with other statins.

Comparative studies have shown the potential benefits of rosuvastatin in secondary prevention and high intensity therapy.

If this article contains identifiable human subject s author s were required to supply signed patient consent prior to publication. The trial was stopped after a median follow-up of 1. This, coupled with its minimal CYP metabolism confers relatively better tolerability, safety and drug interaction profile.


Certain patient groups such as those with renal failure and the elderly are at increased risk of statin related myopathy and rhabdomyolysis. A randomised double blind double-dummy, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of rosuvastatin 10 mg and 20 mgand atorvastatin 10 mg and 20 mg in patients with type 2 diabetes mellitus ANDROMEDA showed that rosuvastatin produced greater reductions in LDL-C, ApoB and total cholesterol when compared with equal doses of atorvastatin.

Soran H, Durrington P. Consistent effects were observed in all subgroups evaluated. A greater proportion of patients on rosuvastatin achieved European LDL-C goals compared to those on atorvastatin.

Rosuvastatina y el estudio JUPITER by Ybel Fermin on Prezi

Another series of sub analyses have looked at lipid profiles and hsCRP particularly in relation to residual cardiovascular risk. Rosuvastatin in renal disease Advanced kidney disease is associated with high cardiovascular morbidity and death.

The associated morbidity and mortality is positively correlated to low density lipoprotein cholesterol LDL-C and inversely related to high density lipoprotein cholesterol HDL-C. It was a randomised, double blind, placebo-matched, multicentre trial involving patients aged 60—80 years. Rosuvastatin in diabetes Type 2 diabetes is associated with increased risk of coronary heart disease. Support Center Support Center.

Unintended effects of statins in men and women in England and Wales: Drugs that reduce plasma concentrations of rosuvastatin. All statins were associated with a dose dependent increased risk of liver dysfunction.

We will also review clinical studies with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins.

These benefits were present in all patient groups including women, non smokers and other low risk patients. Patients on HAART should be considered jupitet treatment with rosuvastatin whenever their treatment allows.

The safety of rosuvastatin as used in common clinical practice: The risk was higher in older participants of the statin trials. The mean volume of distribution is litres in steady state.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. There are no known drug interactions between rosuvastatin and non nucleoside reverse transcriptase inhibitors NNRTIs.


Finally we address its place in clinical practice. The observed increase in HDL-C was transient. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase ApoA-1 ratio at 3 months when compared with atorvastatin 80 mg. For these purposes, rosuvastatin 40 mg daily was the most optimal treatment based on prices for statins, providing generic atorvastatin 80 mg was not available. It must be noted that the study was non-comparative and open label.

A large proportion of these patients are on multiple drug therapy and thus it is crucial to limit pill burden and avoid drug interactions. Previously, there has been limited data on statin benefits in women, black and Hispanic patients.

In the United Kingdom, data from the Health Surveys for England suggest that while mortality may be declining, cardiovascular disease morbidity continues to rise. Clinical studies have demonstrated the benefits of statins in primary prevention. Author s have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material.

New Eng J Med. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Its potential impact in primary and secondary prevention of cardiovascular disease in different groups including heart failure, elderly, renal failure and diabetes, and also in combination with other lipid lowering drugs is the subject of ongoing clinical studies.

Long-term Intervention with Pravastatin in Ischaemic Disease.